As of 30 Sep 2025, 229 institutional investors reported holding 102,790,896 shares of Summit Therapeutics Inc. - COM (SMMT).
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 1,282,044 | $22,446,744 | -$13,186,187 | $17.49 | 26 |
| 2025 Q3 | 102,790,896 | $2,124,232,954 | +$101,213,404 | $20.66 | 229 |
| 2025 Q2 | 97,848,320 | $2,079,803,739 | +$34,103,835 | $21.28 | 225 |
| 2025 Q1 | 97,733,829 | $1,887,229,142 | +$89,016,064 | $19.29 | 199 |
| 2024 Q4 | 92,613,844 | $1,652,162,078 | +$117,836,335 | $17.84 | 194 |
| 2024 Q3 | 84,474,771 | $1,848,145,011 | +$298,396,085 | $21.90 | 164 |
| 2024 Q2 | 72,164,786 | $562,895,901 | +$185,636,664 | $7.80 | 118 |
| 2024 Q1 | 49,654,473 | $205,842,486 | +$72,450,894 | $4.14 | 102 |
| 2023 Q4 | 32,347,368 | $84,434,113 | +$2,186,340 | $2.61 | 93 |
| 2023 Q3 | 32,310,209 | $60,420,216 | -$5,139,413 | $1.87 | 91 |
| 2023 Q2 | 34,903,696 | $87,605,995 | +$36,385,283 | $2.51 | 96 |
| 2023 Q1 | 21,131,959 | $36,976,249 | +$21,762,761 | $1.75 | 86 |
| 2022 Q4 | 8,101,933 | $34,536,890 | +$22,599,596 | $4.25 | 57 |
| 2022 Q3 | 3,172,802 | $3,773,379 | -$5,112,229 | $1.19 | 37 |
| 2022 Q2 | 8,456,620 | $8,456,000 | -$4,226,540 | $1.00 | 33 |
| 2022 Q1 | 10,947,648 | $26,824,000 | -$299,864 | $2.45 | 44 |
| 2021 Q4 | 11,033,765 | $29,678,000 | +$54,239 | $2.69 | 49 |
| 2021 Q3 | 10,933,895 | $54,779,617 | -$944,411 | $5.01 | 50 |
| 2021 Q2 | 11,040,017 | $82,356,721 | +$14,136,648 | $7.46 | 52 |
| 2021 Q1 | 9,283,184 | $54,489,348 | +$1,359,001 | $5.87 | 36 |
| 2020 Q4 | 9,061,824 | $42,589,259 | +$2,512,909 | $4.70 | 31 |
| 2020 Q3 | 7,749,222 | $26,750,440 | +$26,750,440 | $3.44 | 15 |